Tradestie Institutional Equity Comparison Engine
CRMD vs OGEN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRMD Overall Edge
CRMD Captures Institutional Edge (3โ1 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin, Momentum & Technical while OGEN counters with relative strength in Options & Structure. Fundamentally, CRMD trades at 49.0x Forward P/E with 41.0% operating margin (-47.7% YoY revenue) versus OGEN at N/M Forward P/E and 0.0% operating margin (-91.3% YoY). In options structure, CRMD sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against OGEN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
CRMD
CRMD 49.0x vs OGEN N/M Fwd P/E
Growth & Margin Winner
CRMD
Op Margin 41.0% vs 0.0% ยท YoY -47.7% vs -91.3%
Momentum & Technical Winner
CRMD
1Y -56.2% vs -83.7% ยท 52W Pos 3% vs 2%
Options & Structure Winner
OGEN
BREAKDOWN (25th %ile IV) vs UNCLASSIFIED (N/A IV)
CRMD
NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap
$384.7M
1M Return
-32.3%
1Y Return
-56.16%
Forward P/E
49.0x
Unified AI Score
53.2 / 100
HOLD
Tech 60.0
Fund 60.0
Flow 69.0
Mom 55.0
OGEN
NYSE American
Oragenics Inc.
Pharmaceutical Preparations
$0.19
-7.36% 1D
Market Cap
$1.6M
1M Return
-57.19%
1Y Return
-83.67%
Forward P/E
N/M
Unified AI Score
41.7 / 100
SELL
Tech 25.0
Fund 46.0
Flow 50.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRMD -56.16%
OGEN -83.67%
Spread: +27.51 pp (CRMD Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRMD Revenue | OGEN Revenue | CRMD Op. Margin | OGEN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -6250.4% | N/A | CRMD |
| FY2019 | $0M | N/A | -7416.3% | N/A | CRMD |
| FY2020 | $0M | N/A | -11378.4% | N/A | CRMD |
| FY2021 | $0M | $0M | -15417.5% | -18130.3% | CRMD |
| FY2022 | $0M | $0M | -46819.9% | -10964.6% | OGEN |
| FY2023 | N/A | $0M | N/A | -55519.9% | OGEN |
| FY2024 | $40M | N/A | -51.4% | N/A | CRMD |
| FY2025 | $310M | N/A | 48.2% | N/A | CRMD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRMD | OGEN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $384.7M | $1.6M | Larger Scale | CRMD |
| Trailing P/E Ratio Valuation | 2.4x | N/M | Lower Multiple | CRMD |
| Forward P/E Ratio Valuation | 49.0x | N/M | Lower Multiple | CRMD |
| Revenue Growth (YoY) Growth | -47.7% | -91.3% | Higher Growth | CRMD |
| Operating Margin (TTM) Profitability | 41.0% | 0.0% | Higher Margin | CRMD |
| Net Profit Margin Profitability | 15.5% | 0.0% | Higher Margin | CRMD |
| Return on Equity (ROE) Capital Efficiency | 15.3% | -1307.1% | Higher ROE | CRMD |
| 52-Week Range Position Momentum | 3% ($5โ$13) | 2% ($0โ$1) | Stronger Trend | CRMD |
| Beta / 30D Volatility Risk Regime | 1.20ฮฒ ยท 107% Vol | 1.18ฮฒ ยท 153% Vol | Lower Realized Risk | CRMD |
| Unified Institutional Score Composite Signal | 53.2 / 100 (HOLD) | 41.7 / 100 (SELL) | Higher Composite | CRMD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRMD vs OGEN Buy Guide
CRMD
BREAKDOWN
109d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
25th %ile
IV Regime
Compressed (<25th %ile)
OGEN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRMD nor OGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.